Dilon Technologies
Dilon Technologies is a privately held medical device company that develops and markets surgical devices for breast cancer surgery and biosurgery, including the FDA-approved MarginProbe system for real-time intraoperative margin assessment, HEMOBLAST Bellows hemostat, and Navigator gamma probes, serving hospitals and breast centers across 76+ countries.
- Company typePrivate
- Founded2004
- HeadquartersNewport News, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dilon Technologies does
Dilon Technologies, Inc. is a privately held medical device company headquartered in Newport News, Virginia, with an operational facility in Caesarea, Israel. Founded around 1999-2004, the company develops, manufactures, and sells surgical devices organized around two pillars: women's healthcare (breast cancer surgery) and biosurgery (surgical hemostasis and adjunct technologies). Its flagship product, MarginProbe, is the only FDA-approved device for real-time intraoperative margin assessment during breast-conserving surgery, using patented radio-frequency spectroscopy to differentiate cancerous from healthy tissue on the surface of excised lumpectomy specimens; a next-generation MarginProbe 2 received FDA approval in December 2025. The company acquired the MarginProbe technology through its 2020 purchase of substantially all assets of Dune Medical.
The broader portfolio includes HEMOBLAST Bellows (the only combination powdered surgical hemostat containing thrombin, collagen, and chondroitin sulfate, manufactured by subsidiary Dilon Technologies France SAS), the Navigator 2.0 wireless gamma probe system for lymphatic mapping and tumor localization, the TrueView 200 Pro specimen radiography system with automated calcification recognition, and the CoPilot VL+ portable video laryngoscope. These products are sold through a hybrid go-to-market model combining a direct enterprise field sales force (historically ~20 U.S. sellers) targeting hospitals, breast centers, and surgical facilities, plus an international distribution network reaching 76+ countries. In April 2026 Dilon entered an exclusive U.S. distribution agreement for HEMOBLAST Bellows with Xtant Medical, transferring its U.S. sales team into Xtant's commercial organization.
Revenue is generated primarily through hardware sales of devices and associated consumables, supplemented by distribution/licensing arrangements such as the Xtant Medical deal. Pricing is not publicly disclosed and follows a contact-sales, multi-year contract model. The company is led by CEO George Makhoul and Chairman Bob Moussa, with Paul Uricchio as Director of Global Marketing. Reported scale signals include 16,000+ patients treated with MarginProbe, 100+ surgeon users, 12+ peer-reviewed publications supporting MarginProbe, and $30.6M of cumulative disclosed equity funding across 2009-2025, most recently a $9M round led by JGB Management in June 2025.
Dilon Technologies firmographics
Firmographics- Name
- Dilon Technologies
- Legal name
- Dilon Technologies, Inc.
- Website
- https://dilon.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Dilon Technologies is a privately held medical device company that develops and markets surgical devices for breast cancer surgery and biosurgery, including the FDA-approved MarginProbe system for real-time intraoperative margin assessment, HEMOBLAST Bellows hemostat, and Navigator gamma probes, serving hospitals and breast centers across 76+ countries.
- Ownership category
- akta.pro rank
Dilon Technologies industry classification
Industry- Product category
- Medical Devices for Women's Healthcare and Surgical Biosurgery
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)
- akta.pro secondary industry
- Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction) (HLAHAGAF)
Keywords
Where Dilon Technologies is headquartered
LocationHeadquarters
- HQ city
- Newport News
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Dilon Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations
Revenue model
- Medical Device Sales: Direct sales of proprietary medical devices including MarginProbe, Navigator systems, TrueView, and CoPilot VL+ to hospitals, surgical centers, and healthcare providers. Revenue generated from hardware sales with associated consumables and accessories.
- Distribution/ Licensing Revenue: Revenue from exclusive distribution agreements such as the U.S. distribution agreement with Xtant Medical for HEMOBLAST Bellows. Company retains product development and manufacturing while partner handles distribution in defined territories.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Request a Demo / Contact Sales |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Dilon Technologies product offering
Product offeringCore offering
Dilon Technologies develops, manufactures, and sells proprietary medical devices for women's healthcare and biosurgery. Its portfolio includes the MarginProbe system for real-time intraoperative margin assessment during breast lumpectomy, HEMOBLAST Bellows powdered surgical hemostat, the Navigator 2.0 wireless gamma probe for lymphatic mapping and tumor localization, the TrueView 200 Pro specimen radiography system, and the CoPilot VL+ portable video laryngoscope. Products are sold to hospitals, breast centers, and surgical facilities globally.
Product overview
Dilon Technologies is a women's healthcare company that has expanded into biosurgery, developing, manufacturing, and promoting innovative medical devices. The portfolio includes MarginProbe (RF-based intraoperative margin assessment for breast cancer surgery), HEMOBLAST Bellows (topical hemostatic agent for surgical bleeding), Navigator 2.0 (wireless gamma probe for lymphatic mapping and tumor localization), TrueView 200 Pro (specimen radiography system for breast tissue imaging), and CoPilot VL+ (video laryngoscope for airway management). The company operates globally across 76 countries with over 20 years in medical devices.
Differentiator
Problem solved
Functional benefit
Brands
- Navigator: Radio-guided surgical gamma probe system for lymphatic mapping and tumor localization
- MarginProbe
- HEMOBLAST Bellows
- CoPilot VL+
- TrueView
Products and services
- MarginProbe
Quantifiable outcome
- 23%-88% relative reduction in re-excision rates with MarginProbe
- +7 more outcomes
Companies that use Dilon Technologies
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Dilon Technologies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Dilon Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and strategic.
- Xtant Medical HoldingscoreXtant Medical acquired exclusive U.S. distribution rights to Dilon Technologies' HEMOBLAST Bellows hemostatic product. As part of the agreement, Xtant hired Dilon's approximately 20-person U.S. sales team. The deal targets the estimated $2.0 billion global addressable market for hemostatic products and expands Xtant's surgical portfolio.
- Dune MedicalcoreDilon Technologies acquired substantially all assets of Dune Medical, including MarginProbe product line. The acquisition added the only FDA-approved device for intraoperative margin assessment during breast conservation surgery. Synergy achieved through combination of Dilon's Navigator Gamma Probes and MarginProbe for comprehensive breast cancer surgical solutions.
- GE HealthcarestrategicFDA clearance obtained for dual head MBI (Molecular Breast Imaging) localization accessory for breast biopsy, developed in collaboration with GE Healthcare. Represents product integration for breast imaging capabilities.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Dilon Technologies competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights6 records
Customer concentration
Dilon Technologies social profiles
Digital presenceDilon Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dilon Technologies leadership team
Management profileNumber of profiles
Profiles4 records
Dilon Technologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
Dilon Technologies funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dilon Technologies M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dilon Technologies
What does Dilon Technologies do?
Dilon Technologies develops, manufactures, and sells proprietary medical devices for women's healthcare and biosurgery. Its portfolio includes the MarginProbe system for real-time intraoperative margin assessment during breast lumpectomy, HEMOBLAST Bellows powdered surgical hemostat, the Navigator 2.0 wireless gamma probe for lymphatic mapping and tumor localization, the TrueView 200 Pro specimen radiography system, and the CoPilot VL+ portable video laryngoscope. Products are sold to hospitals, breast centers, and surgical facilities globally.
Is Dilon Technologies a public or private company?
Dilon Technologies is a private company. It is classified as unknown and is currently operating.
When was Dilon Technologies founded?
Dilon Technologies was founded in 2004. It employs 51 to 100 people.
Where is Dilon Technologies based?
Dilon Technologies is headquartered in Newport News, United States, in the North America region.
How does Dilon Technologies make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are distribution/ Licensing Revenue.
Does Dilon Technologies have an API?
No public API is recorded for Dilon Technologies.
What industry is Dilon Technologies in?
Dilon Technologies's product category is Medical Devices for Women's Healthcare and Surgical Biosurgery. Its primary akta.pro industry code is HLAHADAL, Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets), with a secondary code of HLAHAGAF, Airway Management Devices (ET Tubes, LMAs, Tracheostomy, Suction). Its NAICS code is 339113 and its SIC code is 3841.